Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AB 201

Drug Profile

AB 201

Alternative Names: AB201-Arca Biopharma; NAPc2; Nematode Anticoagulant Protein c2; Recombinant NAPc2; Recombinant Nematode Anticoagulant c2; rNAPc2

Latest Information Update: 06 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dendreon Corporation
  • Developer ARCA biopharma Inc
  • Class Anti-inflammatories; Anticoagulants; Antivirals; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors; Tissue factor-factor VIIa complex inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ebola virus infections
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II/III Blood coagulation disorders; COVID 2019 infections
  • Preclinical Marburg virus disease
  • Discontinued Acute coronary syndromes; Colorectal cancer; Deep vein thrombosis; Disseminated intravascular coagulation; Ebola virus infections

Most Recent Events

  • 31 Mar 2022 Efficacy and safety data from phase a phase IIb/III ASPEN-COVID-19 trial in COVID-2019 infections and Blood coagulation disorders released by ARCA biopharma
  • 19 Jan 2022 ARCA biopharma completes its phase IIb/III ASPEN-COVID-19 trial in COVID-2019 infections (In adults, In the elderly) and Blood coagulation disorders (In adults, In the elderly) in USA, Argentina and Brazil (SC) (NCT04655586)
  • 02 Dec 2021 ARCA biopharma completes enrollment in a phase IIb ASPEN-COVID-19 trial in COVID-2019 infections in USA, Argentina and Brazil
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top